USA: A retrospective cohort study has found that low testosterone levels in patients with prostate cancer undergoing active ...

Low testosterone levels may increase the risk of higher-grade “extreme” progression of prostate cancer among men enrolled in active surveillance (AS), acc ...

Results challenge view that high testosterone fuels prostate cancer growth ...

Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 TALAPRO-3 study of TALZENNA® (talazoparib), ...

Pfizer is eyeing an earlier use of its PARP inhibitor Talzenna after a positive phase 3 trial in metastatic hormone-sensitive prostate cancer (mHSPC). | After an FDA snub in a broader metastatic ...

While sales of Talzenna, which Pfizer acquired in a $14 billion deal, have been “negligible” so far, the new results should justify use in earlier lines of care, one analyst said.

Molecular profiling of tumors has been shown to improve risk stratification, and it may be useful for prostate cancer active surveillance.

Metastatic prostate cancer is currently associated with high morbidity and mortality rates. In addition, patients respond very differently to standard treatments such as hormone therapy or radiation ...

The statistics are sobering and undeniable — African American men develop prostate cancer at twice the rate of white men and are more likely to die from the disease. This reality makes understanding ...

A new study led by researchers at The University of Texas MD Anderson Cancer Center found that prostate cancer patients with low testosterone levels may have a higher risk of cancer progressing to a ...

Pfizer PFE reported positive top-line results from a late-stage study evaluating Talzenna (talazoparib), an oral PARP inhibitor, in combination with Xtandi (enzalutamide), an ARP inhibitor. The ...